Strategic Report Financial Review Dear shareholder In 2014, we continued to balance our investment for long-term growth against exploiting brand-launch opportunities in the short-term.
We also continued to follow the science and invest in our key therapeutic areas.
Our financial performance in 2014 reflected Core other income in the year was up 64% Contents continued progress from our growth at $1.2 billion, with milestone income related platforms, which grew 15% in the year and to the launch of Nexium OTC being the 70 Introduction now contribute 53% of total revenue.
largest driver of the increase.
Brilinta Brilique showed steady progress 71 Business background and results globally and diabetes growth was strong, Core operating profit fell by 13% to overview with a successful Farxiga Forxiga launch $6.9 billion.
Reported operating profit, at 72 Measuring performance and good US Bydureon Pen uptake, $2.1 billion, was adversely affected by fair building further momentum since the value and other charges related to the 73 Results of operations summary acquisition of BMSs share of the global acquisition of BMSs share of the global analysis of year to 31 December 2014 diabetes alliance in February 2014. diabetes alliance.
75 Cash flow and liquidity Emerging Markets were up 12%, with Chinagrowth of 22%, making China Cash generated from operating activities 77 Financial position AstraZenecas second largest market.
in 2014 was $7.1 billion, as we continued 80 Capitalisation and shareholder return to focus on freeing up cash and improving Investment in business development working capital management.
Our robust 81 Future prospects continued to be an important element in 2014 balance sheet was reflected in strong 81 Financial risk management accelerating the return to growth.
In addition investment-grade ratings in the year.
We to the acquisition of the diabetes franchise, ended the year with net debt of $3.2 billion 82 Critical accounting policies and the strategic transaction with Almirall in while maintaining a significant level of cash estimates respiratory disease further builds the scope to give us financial flexibility.
85 Sarbanes-Oxley Act Section 404 and strength of our respiratory business.
Overall, the selective investment in our growth platforms, which balances both strategic initiatives with short-term opportunities, increased Core SG&A costs by 16% to $10.2 billion in 2014.
Marc Dunoyer Core R&D expense in the year was up Chief Financial Officer 15% to $4.9 billion, reflecting the conscious investment in our rapidly expanding late-stage pipeline, which has yielded an industry-leading six NDA BLA approvals in the year.
70 AstraZeneca Annual Report and Form 20-F Information 2014 Strategic Report The risk of competition from generics The most significant features of our financial following loss of patent protection or results in 2014 are: patent expiry of one of our products or Our financial an at risk launch by a competitor or the Revenue up 3% to $26,095 million launch of a generic competitor in the Actual: 1%.
performance in 2014 same class as one of our products, with A change in accounting related to the US reflected continued the potential adverse effects on sales Branded Pharmaceutical Fee reduced volumes and prices.
Details of patent revenue by $113 million: excluding this progress from our growth expiries for our key marketed products effect, CER growth would have been 4%.
platforms, which grew are included in Patent Expiries from Revenues of our growth platforms page 201. increased 15% in 2014 and constituted 15% in the year and now The adverse impact on pharmaceutical 53% of our total revenue, with contribute 53% of prices as a result of the macroeconomic Brilinta Brilique up 70%, reflecting and regulatory environment.
For instance, continued global progress.
although there is no direct governmental Diabetes up 139%, reflecting 100% control on prices in the US, action from ownership of the diabetes franchise, federal and state programmes and health the strong Farxiga Forxiga launch and insurance bodies is leading to downward good uptake of new Bydureon Pen in pressures on realised prices.
The purpose of this Financial Review is parts of the world, there are a variety of Respiratory up 10%, with Emerging to provide a balanced and comprehensive price and volume control mechanisms Markets growth of 27% and analysis of the financial performance of the and retrospective rebates based on sales decelerating US growth of 15%.
business during 2014, the financial position levels that are imposed by governments.
Emerging Markets up 12%, with China as at the end of the year, and the main The timings of new product launches, growth of 22%, making China business factors and trends that could which can be influenced by national AstraZenecas second largest market.
affect the future financial performance of regulators, and the risk that such new Japan down 3% due to mandated the business.
products do not succeed as anticipated, biennial price cuts, increased use of together with the rate of sales growth and generics and a Nexium recall in the All growth rates in this Financial Review are costs following new product launches.
expressed at CER unless noted otherwise.
Our functional and Core operating profit was down 13% reporting currency is the US dollar, but Actual: 17% to $6,937 million, as we Business background and results we have substantial exposures to other invested in our growth platforms and overview currencies, in particular the euro, accelerated pipeline.
The business background is covered in Japanese yen, pound sterling, Chinese Reported operating profit was down the Marketplace section from page 14, the renminbi and Swedish krona.
Total Therapy Area Review from page 32 and the Macro factors such as greater demand restructuring costs associated with the Geographical Review from page 220, and from an ageing population and increasing global programme to reshape the cost describes in detail the developments in both requirements of Emerging Markets.
base of our business were $1,558 million our products and the geographical regions in 2014. in which we operate.
Over the longer term, the success of our Core operating margin of 26.6% of R&D is crucial and we devote substantial revenue was down 5.0 percentage points As described earlier in this Annual Report, resources to this area.
The benefits of this Actual: 6.0 percentage points.
Reported sales of our products are directly influenced investment are expected to emerge over the operating margin was 8.2% of revenue.
by medical need and are generally paid for long term and there is considerable inherent Core EPS for the full year was $4.28, by health insurance schemes or national uncertainty as to whether and when it will down 8% Actual: 15%.
Our operating results generate future products.
decline compared with Core operating can be affected by a number of factors profit was largely due to a lower tax rate.
other than the delivery of operating plans Reported EPS was down 34% Actual: and normal competition, such as: 52% to $0.98.
Dividends paid increased to $3,521 million 2013: $3,461 million.
AstraZeneca Annual Report and Form 20-F Information 2014 71 Strategic Report Financial Review continued Measuring performance Constant exchange rate CER growth As shown in the 2014 Reconciliation of The following measures are referred to in rates.
These are also non-GAAP Reported results to Core results table on this Financial Review when reporting on our measures.
These measures remove the page opposite, our reconciliation of performance both in absolute terms, but the effects of currency movements Reported financial information to Core more often in comparison to earlier years: by retranslating the current years financial measures includes a breakdown performance at previous years exchange of the items for which our Reported financial Reported performance.
Reported rates and adjusting for other exchange information is adjusted and a further performance takes into account all the effects, including hedging.
A reconciliation breakdown by specific line item as such factors including those which we cannot of the Reported results adjusted for items are reflected in our Reported income influence, principally currency exchange the impact of currency movements is statement.
This illustrates the significant rates that have affected the results of provided in the 2014 Reported operating items that are excluded from Core financial our business, as reflected in our Group profit table on the page opposite.
measures and their impact on our Reported Financial Statements prepared in Gross and operating margin percentages.
financial information, both as a whole and accordance with IFRSs as adopted These measures set out the progression in respect of specific line items.
by the EU and as issued by the IASB.
of key performance margins and illustrate Core financial measures.
These are the overall quality of the business.
Management presents these results non-GAAP measures because, unlike Prescription volumes and trends for key externally to meet investors requirements Reported performance, they cannot products.
These measures can represent for transparency and clarity.
Core financial be derived directly from the information the real business growth and the measures are also used internally in the in the Groups Financial Statements.
progress of individual products better and management of our business performance, These measures are adjusted to exclude more immediately than invoiced sales.
in our budgeting process and when certain significant items, such as Net funds debt.
This represents our cash determining compensation.
amortisation and impairment of and cash equivalents, current investments intangibles, including impairment and derivative financial instruments less Core financial measures are non-GAAP reversals but excluding any charges interest-bearing loans and borrowings.
All items for which Core financial relating to IT assets measures are adjusted are included in charges and provisions related to our CER measures allow us to focus on the our Reported financial information as they global restructuring programmes this changes in sales and expenses driven represent actual costs of our business will include such charges that relate to by volume, prices and cost levels relative in the periods presented.
As a result, Core the impact of our global restructuring to the prior period.
Sales and cost growth financial measures merely allow investors programmes on our capitalised IT expressed in CER allows management to differentiate between different kinds assets to understand the true local movement of costs and they should not be used in other specified items, principally in sales and costs, in order to compare isolation.
You should also refer to our comprising legal settlements and recent trends and relative return on Reported financial information in the 2014 acquisition-related costs, which include investment.
CER growth rates can be used Reported operating profit table on the page fair value adjustments and the imputed to analyse sales in a number of ways but, opposite, our reconciliation of Core financial finance charge relating to contingent most often, we consider CER growth by measures to Reported financial information consideration.
products and groups of products, and by in the Reconciliation of Reported results to In determining the adjustments to arrive countries and regions.
CER sales growth Core results table on the page opposite, at the Core result, we use a set of can be further analysed into the impact of and to the Results of operations summary established principles relating to the sales volumes and selling price.
Similarly, analysis of year to 31 December 2013 nature and materiality of individual items CER cost growth helps us to focus on the section from page 229 for our discussion of or groups of items, excluding, for real local change in costs so that we can comparative Actual growth measures that example, events that i are outside the manage the cost base effectively.
reflect all factors that affect our business.
normal course of business, ii are incurred Our determination of non-GAAP measures, in a pattern that is unrelated to the trends We believe that disclosing Core financial and our presentation of them within this in the underlying financial performance of and growth measures, in addition to our financial information, may differ from our ongoing business, or iii are related to Reported financial information, enhances similarly titled non-GAAP measures of major acquisitions, to ensure that investors ability to evaluate and analyse other companies.
investors ability to evaluate and analyse the underlying financial performance of the underlying financial performance of our ongoing business and the related key The SET retains strategic management of our ongoing business is enhanced.
The adjustments made to the costs excluded from Reported financial the 2014 Reconciliation of Reported our Reported financial information in order information in arriving at Core financial results to Core results table on the to show Core financial measures illustrate measures, tracking their impact on opposite page for a reconciliation of clearly, on a year-on-year or period-byReported operating profit and EPS, with Reported to Coreperformance.
period basis, the impact on our performance operational management being delegated caused by factors such as changes in sales on a case-by-case basis to ensure clear and expenses driven by volume, prices accountability and consistency for each and cost levels relative to such prior years cost category.
72 AstraZeneca Annual Report and Form 20-F Information 2014 Strategic Report Results of operations summary analysis of year to 31 December 2014 2014 Reported operating profit 2014 2013 Percentage of sales 2014 compared with 2013 Growth due to CER exchange Reported Reported CER Actual Reported growth effects Reported 2014 2013 growth growth $m $m $m $m % % % % Revenue 26,095 833 449 25,711 3 1 Cost of sales 5,842 572 9 5,261 22.4 20.5 11 11 Gross profit 20,253 261 458 20,450 77.6 79.5 1 1 Distribution costs 324 23 5 306 1.2 1.2 7 6 Research and development 5,579 716 42 4,821 21.4 18.7 15 16 Selling, general and administrative costs 13,000 896 102 12,206 49.8 47.5 7 7 Other operating income and expense 787 218 26 595 3.0 2.3 37 32 Operating profit 2,137 1,156 419 3,712 8.2 14.4 31 42 Net finance expense 885 445 Share of after tax losses of joint ventures 6 Profit before tax 1,246 3,267 Taxation 11 696 Profit for the period 1,235 2,571 Basic earnings per share $ 0.98 2.04 2014 Reconciliation of Reported results to Core results Core 2014 Acquisition of Intangible compared with 2013 BMSs share Legal amortisation 2014 of diabetes provisions 2014 CER Actual Restructuring and Reported alliance and other Core growth growth costs impairments $m $m $m $m % % $m $m Gross profit 20,253 107 701 146 21,207 3 1 Gross margin % 77.6% 81.3% Distribution costs 324 324 7 6 Research and development 5,579 497 141 4,941 15 16 Selling, general and administrative costs 13,000 662 811 932 379 10,216 16 15 Other operating income and expense 787 292 230 98 1,211 64 61 Operating profit 2,137 1,558 1,883 1,078 281 6,937 13 17 Operating margin % 8.2% 26.6% Net finance expense 885 345 47 493 Taxation 11 255 376 356 42 1,040 Basic earnings per share $ 0.98 1.03 1.19 0.85 0.23 4.28 Each of the measures in the Core column in the above table is a non-GAAP measure.
As detailed above, all growth rates in this US revenue was up 4% Actual: 4% to Fee, imposed by the healthcare reform section are expressed at CER unless $10,120 million, with Europe down 1% legislation in 2010, is recognised.
Established the new regulations, the fee will be based ROW was down 4% Actual: 12% at on actual sales in the current year, which Revenue for the year was up 3% at CER to $3,510 million.
Emerging Markets were up necessitated an additional years charge $26,095 million up 1% on an Actual basis.
12% Actual: 8% to $5,827 million, mainly to be recognised in 2014.
In line with other Accelerating performance of the Groups driven by growth in China of 22% Actual: pharmaceutical industry peers, we growth platforms as defined on page 11 22% to $2,242 million.
China became our previously accrued for this charge based on more than offset the impact of volume second largest market in 2014.
Further prior years sales and recorded the charge erosion on mature brands including details of our sales performance are as a cost in SG&A.
The final regulation has Nexium in the US and pricing pressures contained in the Geographical Review two impacts on the Groups results: in Established Markets.
Excluding the from page 220. additional revenue from the acquisition of BMSs share of the global diabetes In mid 2014, the US Internal Revenue alliance and the impact of the US Branded Service issued final regulations that affected Pharmaceutical Fee restatement as detailed how the annual US Branded Pharmaceutical below, revenue was stable.
AstraZeneca Annual Report and Form 20-F Information 2014 73 Strategic Report Financial Review continued As the fee is now calculated on actual was greater than the decline in revenue in Note 18 to the Financial Statements sales in the current year, AstraZeneca primarily due to expenditure associated with on page 161. considers it more appropriate to account the Groups key growth platforms and Net legal provisions and other charges for the fee as a deduction from Revenue strengthened pipeline.
of $328 million 2013: income of rather than a charge to SG&A.
The new $46 million, including a $201 million legislation is effective from July 2014 and, Core EPS was $4.28, down 8% compared charge for the additional years US therefore, AstraZeneca has treated the with last year Actual: 15%.
The smaller Branded Pharmaceutical Fee as detailed charge for the period since July 2014 as decline in Core EPS compared with Core above and $47 million discount unwind a deduction from Revenue rather than operating profit was largely due to a lower charges relating to contingent as a cost in SG&A.
This favourable tax effect was consideration arising on our other effect of reducing revenue by $113 million.
partially offset by an increase in the number business combinations as detailed This presentational change to the income of shares outstanding and a marginally in Note 18 to the Financial Statements statement had no impact on earnings for higher Core finance expense in the year on page 161. the year.
compared with the prior year.
We recorded a catch-up full annual Reported operating profit for the year charge to SG&A, reflecting this new basis, Pre-tax adjustments to arrive at Core profit was down 31% at CER Actual: 42% to in 2014.
The additional years charge was before tax amounted to $5,192 million in $2,137 million.
Reported EPS was down excluded from Core financial measures as 2014 2013: $4,678 million, comprising 34% Actual: 52% to $0.98.
$4,800 million adjustments to operating declines compared with the respective Core profit 2013: $4,678 million and $392 million financial measures are mainly the result of Core gross margin as a percentage of to net finance expenses 2013: $nil.
our enhanced business acquisition activities, revenue was 81.3% in the year, 0.4 Excluded from Core results were: including our acquisition of BMSs share percentage points lower than last year at of the global diabetes alliance, offset by CER Actual: 0.7 percentage points, as the Restructuring costs totalling $1,558 million reduced impairment charges in 2014. effect of an unfavourable product mix, 2013: $1,421 million, incurred as the including additional costs associated with Group continued the fourth phase of Reported net finance expense was the diabetes brands, more than offset the restructuring announced in March $885 million 2013: $445 million.
The benefit of a lower Crestor royalty.
Restructuring costs included increase was driven by $453 million a $292 million loss on disposal of our 2013: $nil for discount unwinds on Core R&D expense in the year was up 15% Alderley Park site.
Further details of our contingent consideration arising on Actual: 16% to $4,941 million, reflecting restructuring programme are given below.
business combinations $391 million increased spend on our late-stage pipeline.
Amortisation totalling $1,784 million 2013: and other long-term liabilities $62 million.
$1,591 million relating to intangible Expenditures in Core SG&A were up 16% assets, except those related to IT and our The Reported taxation charge of $11 million Actual: 15% to $10,216 million, driven by acquisition of BMSs share of the global 2013: $696 million, consisted of a current investments in sales and marketing diabetes alliance which are separately tax charge of $872 million 2013: dedicated to the Groups growth platforms.
The increase was driven $1,398 million and a credit arising from The acquisitions of BMSs share of the by amortisation charges in connection movements on deferred tax of $861 million diabetes alliance and the rights to Almiralls with our Merck exit arrangements.
The current tax charge respiratory franchise added approximately information on our intangible assets is includes a prior period current tax credit of 4,100 employees.
We have approximately contained in Note 9 to the Financial $109 million 2013: charge of $46 million.
34,800 employees working in Sales and Statements from page 153.
Marketing compared to 29,600 in the prior Intangible impairment charges of The tax paid for the year was $1,201 million, year.
The selective investment in our growth $99 million 2013: net $1,712 million, which is 96% of Reported profit and 19% platforms is partially funded by a decline in including a $1,758 million impairment of Core profit.
Further details relating to intangible asset impairments The Reported tax rate for the year was 0.9% Core other income in the year was up 64% are included in Note 9 to the Financial 2013: 21.3%.
This Reported tax rate of Actual: 61% at $1,211 million which, in Statements from page 153.
0.9% was impacted by a one-off benefit addition to royalty income of $586 million, Costs associated with our acquisition of $117 million in respect of the interincludes milestone income of $200 million of BMSs share of the global diabetes governmental agreement of a transfer on the US launch and $50 million on the alliance amounting to $1,423 million.
pricing matter, the non-Core impact of the European launch of Nexium OTC, and Included within this are $407 million revaluation of the fair value of contingent $80 million of income in relation to the of amortisation charges, a contingent consideration arising on business Japanese launch of Forxiga.
consideration fair value uplift charge of combinations charge of $512 million with $529 million reflecting higher expected related tax credit of $157 million, and the Core operating profit in the year was down diabetes portfolio revenues following benefit of the UK Patent Box legislation 13% to $6,937 million.
Core operating the successful integration of the newly $35 million.
Excluding these effects, the margin was 26.6% of revenue, down 5.0 acquired elements, and $345 million of Reported tax rate for the year would have percentage points Actual: 6.0 percentage interest charges relating to a discount been 18.2%.
The Core tax rate for the year points.
The decline in Core operating profit unwind on contingent consideration was 16.2%.
Excluding the benefit from the arising on the acquisition as detailed transfer pricing agreement and Patent Box, 74 AstraZeneca Annual Report and Form 20-F Information 2014 Strategic Report the Core tax rate would have been 18.5%.
The second phase new initiatives were estimated to be Further details relating to movements in our began in 2010 and the restructuring actions $700 million, of which $600 million is cash, taxation balances are included in Note 4 to were completed in 2011. bringing the total anticipated cost of our the Financial Statements from page 145.
The In March 2013, we announced a expansion of the programme is estimated to Reported post tax profit for the year was restructuring programme which was affect approximately 550 positions, bringing $1,235 million, a decrease of 34% Actual: combined with the third phase of the the total global headcount reduction under 52%.
Reported EPS was down 34% programme announced in February 2012 to the Phase 4 programme to around 5,600 Actual: 52% to $0.98.
initially entailed an estimated global Total comprehensive income decreased headcount reduction of about 5,050 over Restructuring charges of $1,558 million were by$2,729 million from the prior year, the 2013 to 2016 period.
The Group is making good resulting in a loss of $271 million.
This was programme of changes was estimated to progress in implementing the fourth phase driven by the decrease in profit for the incur $2.3 billion in one-time restructuring of restructuring announced in the first yearof $1,336 million, and a decrease of charges, of which $1.7 billion were expected quarter of 2013 and the expansion of this $1,393 million in other comprehensive to be cash costs.
The overall Phase 4 programme announced in the first half of income driven by movements in exchange programme remains on track to deliver 2014.
In addition to costs of this programme, rates in our consolidated results of approximately $800 million anticipated the restructuring charge for the year $1,352 million, principally due to the annual benefits by the end of 2016. includes $261 million incurred on integration strengthening of the US dollar against of businesses acquired in the year and pound sterling, the euro and krona, and The Phase 4 programme was expanded in as a result of our decision to exit the losses on the remeasurement of our defined 2013 to include additional activities, such as Westborough site.
benefit pension liability of $766 million in a transformation of our IT organisation and accordance with the requirements of IAS 19 infrastructure, the exit of R&D activities in Final estimates for programme costs, Employee Benefits driven by a reduction Bangalore, India, and the exit from branded benefits and headcount impact in all inthe discount rate applied to our pension generics in certain Emerging Markets to functions are subject to completion of liabilities partially offset by actuarial gains further reduce costs and increase flexibility.
the requisite consultation in the various onour scheme assets.
When completed, the expansion of the areas.
Our priority as we undertake these restructuring programme is expected to restructuring initiatives is to work with Restructuring deliver a further $300 million in annual our affected employees on the proposed Since 2007, we have undertaken significant benefits by the end of 2016, bringing total changes, acting in accordance with efforts to restructure and reshape our anticipated annualised benefits of the relevant local consultation requirements business to improve long-term Phase 4 programme to $1.1 billion.
The first phase was incremental programme costs from these Cash flow and liquidity 2014 All data in this section is on a Reported basis.
Summary cash flows 2014 2013 2012 $m $m $m Net funds debt brought forward at 1 January 39 1,369 2,849 Earnings before interest, tax, depreciation, amortisation and impairment EBITDA 5,419 8,295 10,666 Movement in working capital and short-term provisions 2,508 166 706 Tax paid 1,201 844 2,043 Interest paid 533 475 545 Non-cash and other movements 865 258 424 Net cash available from operating activities 7,058 7,400 6,948 Purchase of intangibles net 1,740 1,281 3,947 Upfront payments on business acquisition 3,804 1,158 1,187 Payment of contingent consideration on business acquisitions 657 Other capital expenditure net 924 673 473 Investments 7,125 3,112 5,607 Dividends 3,521 3,461 3,665 Net share proceeds repurchases 279 482 2,206 Distributions 3,242 2,979 5,871 Other movements 47 99 312 Net debt funds carried forward at 31 December 3,223 39 1,369 AstraZeneca Annual Report and Form 20-F Information 2014 75 Strategic Report Financial Review continued Net funds debt reconciliation 2014 2013 2012 $m $m $m Cash and cash equivalents 6,360 9,217 7,701 Short-term investments 795 796 823 Net derivative financial instruments 465 402 417 Cash, short-term investments and derivatives 7,620 10,415 8,941 Overdraft and short-term borrowings 1,486 992 879 Finance leases 108 102 84 Current instalments of loans 912 766 Loans due after one year 8,337 8,516 9,347 Loans and borrowings 10,843 10,376 10,310 Net debt funds 3,223 39 1,369 Net cash generated from operating $2,703 million, the rights to Almiralls $3,461 million partially offset by proceeds activities was $7,058 million in the year respiratory franchise $876 million and from the issue of shares of $279 million ended 31 December 2014, compared with the acquisition of Definiens $150 million.
2013: $482 million due to the exercise of $7,400 million in 2013.
Reductions in The comparative period of 2013 included share options.
working capital partially offset the lower payments on the completion of the operating profit and higher tax payments.
acquisitions of Pearl Therapeutics, Omthera, At 31 December 2014, outstanding gross Amplimmune and Spirogen.
Further details debt interest-bearing loans and borrowings Working capital movements were principally of our 2014 business acquisitions and their was $10,843 million 2013: $10,376 million.
driven by general increases in trade impact on our cash flows and balance sheet Of the gross debt outstanding at 31 payables and accruals as a result of our are given below.
Investment cash outflows December 2014, $2,446 million is due within increased R&D and SG&A spend, an also include $657 million 2013: $nil of one year 2013: $1,788 million.
increase in the US rebate and chargeback payments against contingent consideration liabilities as described on page 82, an arising on business combinations and Net debt at 31 December 2014 was additional years Branded Pharmaceutical $1,740 million 2013: $1,316 million for the $3,223 million, compared to a net funds Fee and a reduction in trade receivables purchase of other intangible assets, which position of $39 million at the beginning of principally in Japan and the US.
included a $409 million payment to Merck the year, as a result of the net cash outflow on the consummation of our Second Option as described above.
Non-cash and other movements include as detailed in Note 9 to the Financial $512 million relating to fair value adjustments Statements from page 153 and $310 million Off-balance sheet transactions and on contingent consideration arising from on the settlement of pre-existing launchcommitments business combinations.
and sales-related milestones with BMS as We have no off-balance sheet arrangements detailed in Note 24 to the Financial and our derivative activities are nonInvestment cash outflows of $7,125 million Statements on page 170. speculative.
The table below sets out our 2013: $3,112 million included $3,804 million minimum contractual obligations at the 2013: $1,158 million on completion of Net cash distributions to shareholders were year end.
business acquisitions, inclusive of BMSs $3,242 million 2013: $2,979 million, through share of the global diabetes alliance dividends of $3,521 million 2013: Payments due by period Less than Over 2014 2013 1 year 1-3 years 3-5 years 5 years Total Total $m $m $m $m $m $m 1 Bank loans and other borrowings 2,978 2,552 1,596 10,135 17,261 17,015 Finance leases 45 76 9 130 119 Operating leases 100 150 97 91 438 450 Contracted capital expenditure 438 438 481 Total 3,561 2,778 1,702 10,226 18,267 18,065 1 Bank loans and other borrowings include interest charges payable in the period, as detailed in Note 25 to the Financial Statements on page 175.
76 AstraZeneca Annual Report and Form 20-F Information 2014 Strategic Report Financial position 2014 All data in this section is on a Reported basis.
Our agreement significant income statement movements.
The with BMS provides for potential further As detailed in the Results of operations decrease in net assets is broadly due to payments of up to $1.4 billion for future section on page 74, these movements are dividends of $3,532 million and adverse regulatory, launchand sales-related treated as non-Core items in our income movements on exchange taken to reserves milestones, and various sales-related royalty statement analysis.
In 2014, we recorded an of $1,352 million, partially offset by the payments up until 2025.
Our transaction interest charge of $391 million on the Group profit of $1,235 million.
with Almirall includes further payments of discount unwind on contingent up to $1.2 billion for future development, consideration arising on our business Business combinations launch, and sales-related milestones and combinations, and a net fair value uplift on In 2014, we completed three business various other sales-related payments.
All contingent consideration of $512 million combinations these future payments are treated as which resulted in a charge to our income contingent consideration on our balance statement for the same amount driven, The acquisition of BMSs share of the sheet, and are fair-valued using decision principally, by an improved forecast for global diabetes alliance tree analyses, with key inputs including the revenues for our diabetes franchise The acquisition of the rights to Almiralls probability of success, the potential for following the successful integration of respiratory franchise delays and the expected levels of future BMSs share of the former diabetes alliance.
The fair value is updated at each At 31 December 2014, the contingent balance sheet reporting date to reflect our consideration amount held on the balance These acquisitions had a significant effect latest estimate of the probabilities of these sheet amounted to $6,899 million 2013: on the Groups balance sheet and the key inputs.
Given the long-term nature $514 million, as detailed in Note 18 to the results for the year as detailed above.
of our contingent consideration payments, Financial Statements on page 161.
Further Assets and liabilities acquired, and the fair value calculation includes the details of the business combinations, consideration for the acquisitions, are discounting of future potential payments including the strategic background to the summarised overleaf.
to their present value using discount rates transactions, and details of certain ongoing appropriate to the period over which relationships with BMS, are included in Each acquisition included elements of payments are likely to be made.
Both Note 24 to the Financial Statements from consideration that are contingent on future the unwind of this discount, and any page 170. development and or sales milestones, movements of the fair value of the with both the diabetes and respiratory underlying future payments, can result in acquisitions also including royalty payments AstraZeneca Annual Report and Form 20-F Information 2014 77 Strategic Report Financial Review continued Fair values on acquisition BMSs share of Rights to Almiralls Definiens diabetes alliance respiratory franchise Group Total $m $m $m $m Assets acquired: Non-current assets Property, plant and equipment 478 37 515 Goodwill 1,530 311 1,841 Intangible assets 5,746 1,400 355 7,501 Current assets 480 24 504 Current liabilities 278 2 280 Non-current liabilities 84 11 117 212 Total assets 7,872 1,759 238 9,869 Consideration: Upfront cash paid 2,703 878 150 3,731 Contingent consideration 5,169 881 88 6,138 Total consideration 7,872 1,759 238 9,869 Property, plant and equipment Intangible assets amounted to in 2014 is driven by the payment of one Property, plant and equipment increased $20,981 million at 31 December 2014 years royalties under this revised by $192 million to $6,010 million.
Intangible agreement, along with a transfer of of $1,607 million 2013: $816 million, asset additions were $8,548 million $350 million from prepayments to property, including $515 million 2013: $8 million in 2014 2013: $3,217 million, including plant and equipment as detailed above.
arising on business combinations, were product and other rights acquired in offset by depreciation of $776 million 2013: our acquisitions of $7,501 million 2013: Trade and other payables increased by $906 million and disposals of $582 million $2,416 million.
Amortisation in the year $7,163 million in 2014 to $19,877 million, with 2013: $82 million.
Property, plant and was $2,384 million 2013: $1,779 million.
increases of $993 million in trade payables, equipment also increased due to the Impairment charges in the year amounted $677 million of rebates and chargebacks, transfer of a prepayment balance of to $122 million 2013: $2,082 million.
and $5,781 million in other payables, $350 million, which related to amounts including an increase of $6,385 million in paid to BMS for fixed assets under our Further details of our additions to intangible contingent consideration offset by a previous joint operation with BMS: with assets, and impairments recorded, are reduction of one years Shionogi royalty the acquisition of BMSs interest in the included in Note 9 to the Financial payments.
The increase in trade payables diabetes franchise we acquired the Statements from page 153. was driven by our increased in-year R&D underlying property, plant and equipment and SG&A spend in the latter part of the to which this prepayment related.
Receivables, payables and provisions year.
The rebates and chargebacks balance Trade receivables decreased by $752 million includes an additional years US Branded Goodwill and intangible assets to $4,762 million principally driven by Pharmaceutical Fee.
The increase in The Groups goodwill of $11,550 million reductions in Japan and the US.
contingent consideration is shown in the 2013: $9,981 million principally arose on table below.
the acquisition of MedImmune in 2007 and Prepayments and accrued income the restructuring of our US joint venture with decreased by $928 million.
As detailed in The decrease in provisions of $282 million Merck in 1998.
Goodwill of $1,841 million our 2013 Annual Report, in 2013, we in 2014 included $633 million of cash arising on our acquisitions of BMSs share modified the royalty structure under our payments, partially offset by $434 million of the global diabetes alliance $1,530 million global licence agreement for Crestor, which of additional charges recorded in the year.
and the rights to Almiralls respiratory was amended to include fixed minimum and Included within the $434 million of charges franchise $311 million, as detailed in Note maximum annual royalty payments to for the year were $254 million for our global 24 to the Financial Statements from page Shionogi.
These future royalties were restructuring initiative and $91 million in 170, was capitalised in 2014. recognised within payables and as a respect of legal charges.
The reduction in prepayments included $472 million for our global Acquisition of BMSs share of diabetes alliance Other Total $m $m $m At 1 January 2014 514 514 Acquisitions 5,169 969 6,138 Settlements 657 657 Revaluations 529 17 512 Discounting 345 46 391 Foreign exchange 1 1 At 31 December 2014 5,386 1,513 6,899 78 AstraZeneca Annual Report and Form 20-F Information 2014 Strategic Report restructuring programme.
Further details example, in the event of AstraZeneca and In September 2014, AstraZeneca and of the charges made against provisions the pension fund trustee agreeing a change Lilly entered into an agreement to jointly are contained in Notes 19 and 27 to the to the current long-term investment strategy.
develop and commercialise AZD3293, Financial Statements on page 162, and 182 an oral beta secretase cleaving enzyme to 187, respectively.
Further details of the Groups pension BACE inhibitor currently in development schemes are included in Note 20 to the as a potential treatment for Alzheimers Tax payable and receivable Financial Statements from page 162. disease.
AZD3293 is an oral, potent and Net income tax payable has decreased by selective small molecule inhibitor of BACE $557 million to $2,025 million, principally Commitments and contingencies that has been shown in Phase I studies due to cash tax timing differences, foreign The Group has commitments and to significantly and dose-dependently exchange and a $117 million adjustment contingencies that are accounted for in reduce levels of amyloid beta in the in respect of prior periods following the accordance with the accounting policies cerebro-spinal fluid of Alzheimers patients settlement of the inter-governmental described in the Financial Statements in and healthy volunteers.
Under the agreement of a transfer pricing matter.
the Group Accounting Policies section from terms of the agreement, Lilly will pay The tax receivable balance of $329 million page 138.
The Group also has taxation AstraZeneca up to $500 million in 2013: $494 million comprises tax owing contingencies.
These are described in the development and regulatory milestone to AstraZeneca from certain governments Taxation section in the Critical accounting payments.
AstraZeneca expects to expected to be received on settlements of policies and estimates section on page 85 receive the first milestone payment of transfer pricing audits and disputes see and in Note 27 to the Financial Statements $50 million in the first half of 2015.
Note 27 to the Financial Statements from on page 187.
The companies will equally share all page 182 and cash tax timing differences.
future costs for the development and Net deferred tax liabilities decreased by Research and development collaboration commercialisation of AZD3293, as well $1,045 million in the year mainly due to a payments as net global revenues post-launch.
Lilly reversal of taxable temporary differences.
Details of future potential R&D collaboration will lead clinical development, working Additional information on the movement in payments are also included in Note 27 with researchers from AstraZenecas deferred tax balances is contained in Note 4 to the Financial Statements from page 182.
Innovative Medicines Unit for to the Financial Statements from page 145.
As detailed in Note 27 to the Financial neuroscience, while AstraZeneca will Statements, payments to our collaboration be responsible for manufacturing.
The Retirement benefit obligations partners may not become payable due to companies will take joint responsibility Net retirement benefit obligations increased the inherent uncertainty in achieving the for commercialisation of AZD3293.
Employer development and revenue milestones linked In April 2014, AstraZeneca entered into contributions to the pension scheme of to the future payments.
As part of our overall a joint venture agreement with Samsung $184 million and beneficial exchange externalisation strategy, we may enter into Biologics Co. Ltd to develop a biosimilar movements of $268 million were offset by further collaboration projects in the future using the combined capabilities of the two service cost charges of $221 million, net that may include milestone payments and, parties.
The agreement resulted in the financing costs of $92 million and net therefore, as certain milestone payments formation of a joint venture entity based remeasurement adjustments of $766 million, fail to crystallise due to, for example, in the UK, Archigen Biotech Limited, with driven by a reduction in the discount rate development not proceeding, they may be a branch in South Korea.
AstraZeneca applied to our pension liabilities under IAS replaced by potential payments under new contributed $70 million in cash to the joint 19 partially offset by actuarial gains on our collaborations.
venture entity and has a 50% interest in scheme assets.
Further financial details Investments, divestments and capital are contained in Note 10 to the Financial Approximately 97% of the Groups expenditure Statements on page 157. obligations are concentrated in the UK, the The Group has completed over 180 major In March 2013, AstraZeneca signed US, Sweden and Germany.
In recent years, or strategically important business an exclusive agreement with Moderna the Group has undertaken several initiatives development transactions over the past Therapeutics to discover, develop to reduce its net pension obligation three years, eight of which were accounted and commercialise pioneering exposure.
For the UK defined benefit for as business acquisitions under IFRS 3 medicines based on messenger RNA pension scheme, which is AstraZenecas Business Combinations, being the Therapeutics for the treatment of serious largest defined benefit scheme, these acquisitions of BMSs share of the global cardiovascular, metabolic and renal initiatives have included agreeing funding diabetes alliance, the rights to Almiralls diseases as well as cancer.
Under the principles for cash contributions to be paid respiratory franchise and the acquisition terms of the agreement, AstraZeneca into the UK pension scheme to target a level of Definiens in 2014: Pearl Therapeutics, made an upfront payment of $240 million.
of assets in excess of the current expected Omthera, Amplimmune and Spirogen in AstraZeneca will have exclusive access cost of providing benefits, and, in 2010, 2013: and Ardea in 2012, and all others to select any target of its choice in amendments to the scheme to freeze being in-licences, strategic alliances and cardiometabolic and renal diseases, pensionable pay at 30 June 2010 levels.
Further details of our as well as selected targets in oncology, addition to the cash contributions to be paid business acquisitions in the past three years over a period of up to five years for into the UK pension scheme, AstraZeneca are contained in Note 24 to the Financial subsequent development of messenger makes contributions to an escrow account, Statements from page 170.
Details of our RNA Therapeutics.
In addition, Moderna which is held outside the pension scheme.
significant externalisation transactions are Therapeutics is entitled to an additional The escrow account assets are payable to given below: the fund in agreed circumstances, for AstraZeneca Annual Report and Form 20-F Information 2014 79 Strategic Report Financial Review continued $180 million for the achievement of three Japan, Europe, the CIS, the Middle East roxadustat in China where FibroGen will technical milestones.
Through this and South Africa, which are covered by be responsible for clinical trials, regulatory agreement, AstraZeneca has the option an existing agreement between FibroGen matters, manufacturing and medical to select up to 40 drug products for and Astellas.
The AstraZeneca-FibroGen affairs, and AstraZeneca will oversee clinical development and Moderna joint effort will be focused on the promotional activities and commercial Therapeutics will be entitled to development of roxadustat to treat distribution.
development and commercial milestone anaemia in CKD and ESRD, and may be In April 2012, AstraZeneca announced payments as well as royalties on drug extended to other anaemia indications.
an agreement to jointly develop and sales.
AstraZeneca will lead the AstraZeneca and FibroGen plan to commercialise five monoclonal antibodies pre-clinical, clinical development and undertake an extensive roxadustat Phase from Amgens clinical inflammation commercialisation of therapeutics III development programme for the US, portfolio: AMG 139, AMG 157, AMG 181, resulting from the agreement and and to initiate Phase III trials in China, with AMG 557 and brodalumab AMG 827.
Moderna Therapeutics will be responsible anticipated regulatory filings in China in Under the terms of the agreement, for designing and manufacturing the 2016 and in the US in 2018.
Under the AstraZeneca made a $50 million upfront messenger RNA Therapeutics against arrangement, AstraZeneca agreed to pay payment and the companies share both selected targets.
AstraZeneca is currently FibroGen upfront and subsequent costs and profits.
Approximately 65% progressing 19 projects across CVMD non-contingent payments totalling of costs for the 2012 to 2014 period are and Oncology.
Utilising both companies $350 million, as well as potential funded by AstraZeneca.
Thereafter, expertise, significant progress has also development-related milestone payments the companies will split costs equally.
been made to the technology platform, of up to $465 million, and potential future In addition, AstraZeneca will make with the focus on formulation, safety, and sales-related milestone payments, in development milestone payments up drug metabolism and pharmacokinetics.
addition to tiered royalty payments on to launch.
On commercialisation, Amgen In July 2013, AstraZeneca entered into a future sales of roxadustat in the low 20% will retain a low single-digit royalty for strategic collaboration with FibroGen to range.
Additional development milestones brodalumab and a mid single-digit royalty develop and commercialise roxadustat will be payable for any subsequent for the rest of the portfolio after which the FG-4592, a first-in-class oral compound indications which the companies choose companies will share profits equally.
in late-stage development for the to pursue.
AstraZeneca will be treatment of anaemia associated with responsible for the US commercialisation The Group determines the above business chronic kidney disease CKD and of roxadustat, with FibroGen undertaking development transactions to be significant end-stage renal disease ESRD.
This specified promotional activities in the using a range of factors.
We look at the broad collaboration focuses on the US, ESRD segment in this market.
80 AstraZeneca Annual Report and Form 20-F Information 2014 Strategic Report several quantitative and qualitative believes it is appropriate to continue premiums for lower cover, we focus our criteria.
Because we consider business the suspension of the share repurchase insurance resources on the most critical development transactions to be an programme that was announced in areas, or where there is a legal requirement, extension of our R&D strategy, the expected October 2012. and where we can get best value for money.
total value of development payments under Risks to which we pay particular attention the transaction and its proportion of our Future prospects include business interruption, Directors annual R&D spend, both of which are As outlined earlier in this Annual Report, and Officers liability, and property damage.
proxies for overall R&D effort and cost, our strategy is focused on innovation and Insurance for product liability has not been are important elements of the significance returning to growth.
In support of this, available on commercially acceptable terms determination.
Other quantitative criteria we we made certain choices around our for several years and the Group has not apply include, without limitation, expected three strategic priorities.
We described purchased in the market product liability levels of future sales, the possible value of our immediate priorities, mid-term goals insurance since February 2006. milestone payments and the resources used and long-term aspirations.
for commercialisation activities for example, Taxation the number of staff.
Qualitative factors we As we experience a period of patent Tax risk management forms an integrated consider include, without limitation, new expiries: part of the Groups risk management market developments, new territories, new processes.
Our tax strategy is to manage areas of research and strategic implications.
Our immediate priorities are to drive our tax risks and tax costs in a manner on-market revenues through investment consistent with shareholders best long-term In aggregate, payments capitalised under in our growth platforms and portfolio interests, taking into account both economic the Groups externalisation arrangements, of on-market brands.
These include and reputational factors.
We draw a other than those detailed above, amounted products in our three main therapy areas, distinction between tax planning using to $201 million in 2014, $301 million in 2013, and a focus on the Emerging Markets and artificial structures and optimising tax and $156 million in 2012.
We are also pursuing business treatment of business transactions, and recognised other income in respect of other development and investment in R&D.
we engage only in the latter.
externalisation arrangements totalling We have already accelerated a number $400 million in 2014, including $250 million of projects and progressed them into Treasury of income from an agreement with Pfizer for Phase III development.
The principal financial risks to which the OTC rights for Nexium, $20 million in 2013 Our mid-term goals to 2016 are to Group is exposed are those arising from and $255 million in 2012. progress our Phase II pipeline and to liquidity, interest rate, foreign currency exploit the potential of our biologics and credit.
The Group has a centralised Capitalisation portfolio.
treasury function to manage these risks in The total number of shares in issue at 31 Our long-term aspiration to 2020 and accordance with Board-approved policies.
December 2014 was 1,263 million 2013: beyond, in line with our strategic ambition, Specifically, liquidity risk is managed through 1,257 million.
Six million Ordinary Shares is to achieve scientific leadership and maintaining access to a number of sources were issued in consideration of share option sustainable growth, including the launch of funding to meet anticipated funding exercises for a total of $279 million.
requirements, including committed bank Shareholders equity decreased by facilities and cash resources.
Interest rate $3,597 million to $19,627 million at the year We expect 2015 revenue to decline by mid risk is managed through maintaining a debt end.
Non-controlling interests decreased single-digit percent at CER compared to portfolio that is weighted towards fixed rates to $19 million 2013: $29 million.
Consistent with its business model, of interest.
Accordingly, the Groups net the Company will continue to seek interest charge is not significantly affected Dividend and share repurchases externalisation revenue from partnerships by movements in floating rates of interest.
The Board has recommended a second and licensing select products and We monitor the impact of currency on a interim dividend of $1.90 125.0 pence, technologies.
Core EPS is expected to portfolio basis to recognise correlation 15.62 SEK to be paid on 23 March 2015. increase in 2015 by low single-digit percent effect, and may hedge to protect against This brings the full year dividend to $2.80 at CER.
significant adverse impacts on cash flow 178.1 pence, 21.82 SEK.
We also Financial risk management hedge the currency exposure that arises This dividend is consistent with the Financial risk management policies between the booking and settlement dates progressive dividend policy, by which the Insurance on non-local currency purchases and sales Board intends to maintain or grow the Our risk management processes are by subsidiaries and the external dividend.
described in Risk from page 203.
These Credit risk is managed through setting and processes enable us to identify risks that monitoring credit limits appropriate for the The Board regularly reviews its distribution can be partly or entirely mitigated through assessed risk of the counterparty.
policy and its overall financial strategy to the use of insurance.
We negotiate the best continue to strike a balance between the available premium rates with insurance Our capital and risk management objectives interests of the business, our financial providers on the basis of our extensive risk and policies are described in further detail creditors and our shareholders.
In the current in Note 25 to the Financial Statements regard for business investment, funding the insurance market, the level of cover is from page 174 and in Risk from page 203. progressive dividend policy and meeting our decreasing while premium rates are debt service obligations, the Board currently increasing.
Rather than simply paying higher AstraZeneca Annual Report and Form 20-F Information 2014 81 Strategic Report Financial Review continued Sensitivity analysis of the Groups programmes Medicaid best price 2012: $160 million mainly due to the impact exposure to exchange rate and interest rate contracts, supplemental rebates etc.
of price increases on price-protected movements is also detailed in Note 25 to Theycan be classified as follows: business and pricing pressure resulting in the Financial Statements from page 174. higher negotiated rates particularly in the Chargebacks, where we enter into Medicare Part D business.
Critical accounting policies arrangements under which certain and estimates parties, typically hospitals, long-term care Cash discounts are offered to customers Our Financial Statements are prepared in facilities, group purchasing organisations, to encourage prompt payment.
Accruals accordance with IFRSs as adopted by the the Department of Veterans Affairs, Public are calculated based on historical EU adopted IFRS and as issued by the Health Service Covered Entities and the experience and are adjusted to reflect IASB, and the accounting policies employed Department of Defense, are able to buy actual experience.
are set out in the Group Accounting Policies products from wholesalers at the lower section in the Financial Statements from prices we have contracted with them.
Industry practice in the US allows page 138.
In applying these policies, we The chargeback is the difference between wholesalers and pharmacies to return make estimates and assumptions that affect the price we invoice to the wholesaler unused stocks within six months of, and the reported amounts of assets and and the contracted price charged by the up to 12 months after, shelf-life expiry.
liabilities and disclosure of contingent assets wholesaler.
Chargebacks are paid directly The customer is credited for the returned and liabilities.
The actual outcome could to the wholesalers.
product by the issuance of a credit note.
Some of these Regulatory, including Medicaid and other Returned products are not exchanged for policies require a high level of judgement federal and state programmes, where we products from inventory and once a return because the areas are especially subjective pay rebates based on the specific terms claim has been determined to be valid and a or complex.
We believe that the most critical of agreements with the US Department credit note has been issued to the customer, accounting policies and significant areas of of Health and Human Services and with the returned products are destroyed.
At the judgement and estimation are in individual states, which include product point of sale in the US, we estimate the usage and information on best prices quantity and value of products which may revenue recognition and average market prices benchmarks.
Our returns accruals research and development Contractual, under which entities such as in the US are based on actual experience.
impairment testing of goodwill and third party managed-care organisations Our estimate is based on the preceding 12 intangible assets are entitled to rebates depending on months for established products together litigation specified performance provisions, which with market-related information, such as post-retirement benefits vary from contract to contract.
estimated stock levels at wholesalers and taxation.
competitor activity, which we receive via The effects of these deductions on our third party information services.
For newly Revenue recognition USpharmaceuticals revenue and the launched products, we use rates based on Revenue is recorded at the invoiced movements on US pharmaceuticals our experience with similar products or a amount excluding inter-company sales revenue provisions are set out opposite.
and value-added taxes less movements in estimated accruals for rebates and Accrual assumptions are built up on a For products facing generic competition, chargebacks given to managed-care and product-by-product and customer-byour experience is that we usually lose other customers and product returns a customer basis, taking into account specific the ability to estimate the levels of returns particular feature in the US.
It is the Groups contract provisions coupled with expected from wholesalers with the same degree policy to offer a credit note for all returns and performance, and are then aggregated into of precision that we can for products to destroy all returned stock in all markets.
a weighted average rebate accrual rate for still subject to patent protection.
This is Cash discounts for prompt payment are each of our products.
Accrual rates are because we have limited or no insight into also deducted from sales.
Revenue is reviewed and adjusted on a monthly basis.
a number of areas: the actual timing of recognised at the point of delivery, which There may be further adjustments when the generic launch for example, a generic is usually when title passes to the customer, actual rebates are invoiced based on manufacturer may or may not have either on shipment or on receipt of goods utilisation information submitted to us in produced adequate pre-launch inventory : by the customer depending on local trading the case of contractual rebates and claims the pricing and marketing strategy of the terms.
Income from royalties and from invoices are received in the case of competitor: the take-up of the generic: and disposals of IP, brands and product lines regulatory rebates and chargebacks.
We in cases where a generic manufacturer has is included in other operating income.
believe that we have made reasonable approval to launch only one dose size in a estimates for future rebates using a similar market of several dose sizes the likely level Rebates, chargebacks and returns methodology to that of previous years.
of switching from one dose to another.
in the US Inevitably, however, such estimates involve Under our accounting policy, revenue is When invoicing sales in the US, we estimate judgements on aggregate future sales recognised only when the amount of the the rebates and chargebacks that we levels, segment mix and the customers revenue can be measured reliably.
These rebates typically arise contractual performance.
approach in meeting this condition for from sales contracts with third party products facing generic competition will vary managed-care organisations, hospitals, Managed-care and group purchasing from product to product depending on the long-term care facilities, group purchasing organisation rebate charges increased by specific circumstances.
organisations and various federal or state $812 million in 2014 2013: $1,321 million: 82 AstraZeneca Annual Report and Form 20-F Information 2014 Strategic Report Gross to net sales US Pharmaceuticals 2014 2013 2012 $m $m $m Gross sales 23,301 21,345 20,747 Chargebacks 2,794 2,449 2,261 Regulatory US government and state programmes 1,389 1,435 1,426 Contractual Managed-care and group purchasing organisation rebates 7,730 6,918 5,597 Cash and other discounts 436 399 401 Customer returns 295 112 182 Other 537 341 273 Net sales 10,120 9,691 10,607 Movement in provisions US Pharmaceuticals Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2014 current year prior years payments 2014 $m $m $m $m $m Chargebacks 355 2,838 44 2,692 457 Regulatory US government and state programmes 784 1,544 155 1,466 707 Contractual Managed-care and group purchasing organisation rebates 1,714 7,703 27 7,078 2,366 Cash and other discounts 32 436 435 33 Customer returns 222 295 199 318 Other 74 537 448 163 Total 3,181 13,353 172 12,318 4,044 Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2013 current year prior years payments 2013 $m $m $m $m $m Chargebacks 313 2,439 10 2,407 355 Regulatory US government and state programmes 825 1,447 12 1,476 784 Contractual Managed-care and group purchasing organisation rebates 1,348 6,951 33 6,552 1,714 Cash and other discounts 33 399 400 32 Customer returns 211 99 13 101 222 Other 45 341 312 74 Total 2,775 11,676 22 11,248 3,181 Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2012 current year prior years payments 2012 $m $m $m $m $m Chargebacks 395 2,296 35 2,343 313 Regulatory US government and state programmes 1,290 1,585 159 1,891 825 Contractual Managed-care and group purchasing organisation rebates 1,600 5,578 19 5,849 1,348 Cash and other discounts 41 401 409 33 Customer returns 121 117 65 92 211 Other 80 273 308 45 Total 3,527 10,250 110 10,892 2,775 The closing adjustment in respect of to reduce the speculative purchasing practice in the pharmaceutical industry is prior years increased 2014 net US behaviour of the wholesalers and reduce that we own valuable intangible assets pharmaceuticals revenue by 1.7% 2013: short-term fluctuations in the level of which are not recorded on the balance increased revenue by 0.2%: 2012: increased inventory they hold.
We also own acquired intangible revenue by 1.0%.
However, taking into incentives to encourage wholesaler assets which are included on the balance account the adjustments affecting both the speculative buying and attempt, where sheet.
As a consequence of regular reviews current and the prior year, 2013 revenue possible, to restrict shipments to underlying of product strategy, from time to time we was increased by 1.5%, and 2012 revenue demand when such speculation occurs.
sell such assets and generate income.
Sales was reduced by 0.8%, by adjustments of product lines are often accompanied between years.
Sales of intangible assets by an agreement on our part to continue A consequence of charging all internal R&D manufacturing the relevant product for a We have distribution service agreements expenditure to the income statement in the reasonable period often about two years with major wholesaler buyers which serve year in which it is incurred which is normal while the purchaser constructs its own AstraZeneca Annual Report and Form 20-F Information 2014 83 Strategic Report Financial Review continued manufacturing facilities.
The contracts Details of the estimates and assumptions proceedings, from guarantees or from typically involve the receipt of an upfront we make in our annual impairment testing environmental liabilities connected with payment, which the contract attributes of goodwill are included in Note 8 to the our current or former sites.
Where we to the sale of the intangible assets, and Financial Statements on page 152.
The believe that potential liabilities have a less ongoing receipts, which the contract Group, including acquisitions, is considered than 50% probability of crystallising, or attributes to the sale of the product we a single cash-generating unit for impairment where we are unable to make a reasonable manufacture.
In cases where the transaction purposes.
No impairment of goodwill estimate of the liability, we treat them as has two or more components, we account was identified.
These are not provided for the delivered item for example, the for but are disclosed in Note 27 to the transfer of title to the intangible asset as Impairment reviews have been carried Financial Statements from page 182. a separate unit of accounting and record out on all intangible assets that are in revenue on delivery of that component, development and not being amortised, all In cases that have been settled or provided that we can make a reasonable major intangible assets acquired during the adjudicated, or where quantifiable fines and estimate of the fair value of the undelivered year and all intangible assets that have had penalties have been assessed and which component.
Where the fair market value of indications of impairment during the year.
are not subject to appeal or other similar the undelivered component for example, Sales forecasts and specific allocated forms of relief, or where a loss is probable a manufacturing agreement exceeds the costs which have both been subject to more than 50% assessed probability and contracted price for that component, we appropriate senior management sign-off we are able to make a reasonable estimate defer an appropriate element of the upfront are discounted using appropriate rates of the loss, we indicate the loss absorbed or consideration and amortise this over the based on AstraZenecas risk-adjusted, the amount of the provision accrued.
However, where the pre-tax weighted average cost of capital.
fair market value of the undelivered Our weighted average cost of capital Where it is considered that the Group is component is equal to or lower than reflects factors such as our capital structure more likely than not to prevail, or in the rare the contracted price for that component, and our costs of debt and equity.
In building circumstances where the amount of the we treat the whole of the upfront amount to the range of rates used in our internal legal liability cannot be estimated reliably, as being attributable to the delivered investment appraisal of future projects legal costs involved in defending the claim intangible assets and recognise that part and capital investment decisions, we adjust are charged to profit as they are incurred.
of the revenue upon delivery.
No element our weighted average cost of capital for Where it is considered that the Group has of the contracted revenue related to the other factors which reflect, without limitation, a valid contract which provides the right undelivered component is allocated to the local matters such as risk on a case-byto reimbursement from insurance or sale of the intangible asset.
This is because case basis.
otherwise of legal costs and or all or part the contracted revenue relating to the of any loss incurred or for which a provision undelivered component is contingent on A significant portion of our investments in has been established and we consider future events such as sales and so cannot intangible assets and goodwill arose from recovery to be virtually certain, then the best be anticipated.
the restructuring of the joint venture with estimate of the amount expected to be Merck in 1998, the acquisition of received is recognised as an asset.
Research and development MedImmune in 2007, and the payments Our business is underpinned by our to retire Mercks interests in our products Assessments as to whether or not to marketed products and development in the US in 2008, 2010 and 2014.
In recognise provisions or assets and of the portfolio.
The R&D expenditure on internal addition, our recent business combinations, amounts concerned usually involve a series activities to generate these products is as detailed in Note 24 to the Financial of complex judgements about future events generally charged to profit in the year Statements from page 170, have added and can rely heavily on estimates and that it is incurred.
Purchases of IP and significant product, marketing and assumptions.
AstraZeneca believes that the product rights to supplement our R&D distribution intangible rights to our intangible provisions recorded are adequate based on portfolio are capitalised as intangible asset portfolio.
We are satisfied that the currently available information and that the assets.
Further details of this policy are carrying values of our intangible assets as insurance recoveries recorded will be included in the Group Accounting Policies at 31 December 2014 are fully justified by received.
However, given the inherent section of our Financial Statements estimated future cash flows.
The accounting uncertainties involved in assessing the from page 138.
Such intangible assets for our intangible assets, including details of outcomes of these cases and in estimating are amortised from the launch of the our arrangements with Merck, is fully the amount of the potential losses and the underlying products and are tested for explained in Note 9 to the Financial associated insurance recoveries, we could impairment both before and after launch.
Statements from page 153. in future periods incur judgments or This policy is in line with practice adopted insurance settlements that could have by major pharmaceutical companies.
Further details of the estimates and a material adverse effect on our results assumptions we make in impairment testing in any particular period.
Impairment testing of goodwill and of intangible assets are included in Note 9 intangible assets to the Financial Statements.
The position could change over time, and We have significant investments in goodwill there can, therefore, be no assurance that and intangible assets as a result of Litigation any losses that result from the outcome of acquisitions of businesses and purchases In the normal course of business, any legal proceedings will not exceed the of assets, such as product development contingent liabilities may arise from amount of the provisions that have been and marketing rights.
product-specific and general legal booked in the accounts.
84 AstraZeneca Annual Report and Form 20-F Information 2014 Strategic Report Although there can be no assurance Further details of our accounting for units and a number of specialist areas, regarding the outcome of legal proceedings, post-retirement benefit plans are included such as financial consolidation and we do not currently expect them to have in Note 20 to the Financial Statements reporting, treasury operations and taxation, a material adverse effect on our financial from page 162. so that, in aggregate, we have covered position, but they could significantly affect a significant proportion of the key line our financial results in any particular period.
Taxation in our Financial Statements.
Each of these Accruals for tax contingencies require operating units and specialist areas has Post-retirement benefits management to make judgements and ensured that its relevant processes and We offer post-retirement benefit plans which estimates in relation to tax audit issues and controls are documented to appropriate cover many of our employees around the exposures.
Amounts accrued are based standards, taking into account, in particular, world.
In keeping with local terms and on managements interpretation of the guidance provided by the SEC.
We conditions, most of these plans are defined country-specific tax law and the likelihood of have also reviewed the structure and contribution in nature, where the resulting settlement.
Tax benefits are not recognised operation of our entity level control income statement charge is fixed at a set unless the tax positions are probable of environment.
This refers to the overarching level or is a set percentage of employees being sustained.
Once considered to be control environment, including structure pay.
However, several plans, mainly in the probable, management reviews each of reviews, checks and balances that UK which has by far the largest single material tax benefit to assess whether a are essential to the management of scheme, the US and Sweden, are defined provision should be taken against full a well-controlled business.
benefit plans where benefits are based on recognition of the benefit on the basis of employees length of service and final salary potential settlement through negotiation The Directors have concluded that our typically averaged over one, three or five and or litigation.
All such provisions are internal control over financial reporting is years.
The UK and US defined benefit included in current liabilities.
Any recorded effective at 31 December 2014 and the schemes were closed to new entrants in exposure to interest on tax liabilities is assessment is set out in the Directors 2000.
All new employees in these countries provided for in the tax charge.
Responsibilities for, and Report on, are offered defined contribution schemes.
Internal Control over Financial Reporting on AstraZeneca faces a number of transfer page 129.
KPMG Audit LLP has audited the In applying IAS 19 Employee Benefits, pricing audits in jurisdictions around effectiveness of our internal control over we recognise all actuarial gains and losses the world and, in some cases, is in financial reporting at 31 December 2014 immediately through Other Comprehensive dispute with the tax authorities.
These and, as noted in the Auditors Reports on Income.
Investment decisions in respect disputes usually result in taxable profits the Financial Statements and on Internal of defined benefit schemes are based being increased in one territory and Control over Financial Reporting Sarbaneson underlying actuarial and economic correspondingly decreased in another.
Oxley Act Section 404 on page 130, their circumstances with the intention of ensuring Our balance sheet positions for these report is unqualified.
that the schemes have sufficient assets to matters reflect appropriate corresponding meet liabilities as they fall due, rather than relief in the territories affected.
The trustees follow a strategy of awarding Further details of the estimates and mandates to specialist, active investment assumptions we make in determining our Strategic Report managers, which results in a broad recorded liability for transfer pricing audits diversification of investment styles and asset and other tax contingencies are included in The Strategic Report, which has classes.
The investment approach is the Tax section of Note 27 to the Financial been prepared in accordance with intended to produce less volatility in the Statements on page 187. the requirements of the Companies plan asset returns.
Act 2006, comprises the following Sarbanes-Oxley Act Section 404 sections: In assessing the discount rate applied to As a consequence of our NYSE listing, the obligations, we have used rates on AstraZeneca is required to comply with AstraZeneca at a glance AA corporate bonds with durations those provisions of the Sarbanes-Oxley Chairmans Statement corresponding to the maturities of those Act applicable to foreign issuers.
Section Chief Executive Officers Review obligations, except in Sweden where we 404 of the Sarbanes-Oxley Act requires Strategy have used rates on mortgage bonds as the companies annually to assess and make Therapy Area Review market in high-quality corporate bonds is public statements about the quality and Business Review insufficiently deep.
effectiveness of their internal control over Resources Review financial reporting.
As regards SarbanesFinancial Review In all cases, the pension costs recorded in Oxley Act Section 404, our approach is the Financial Statements are assessed in based on the Committee of Sponsoring and has been approved and signed accordance with the advice of independent Organizations COSO 2013 framework.
qualified actuaries, but require the exercise of significant judgement in relation to Our approach to the assessment has A C N Kemp assumptions for long-term price inflation, been to select key transaction and financial Company Secretary and future salary and pension increases.
reporting processes in our largest operating 5 February 2015 AstraZeneca Annual Report and Form 20-F Information 2014 85
